Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Indian drug...

    Indian drug formulation market grew at 15.3 percent in August: Report

    Written by savita thakur thakur Published On 2016-09-26T11:34:26+05:30  |  Updated On 26 Sept 2016 11:34 AM IST
    Indian drug formulation market grew at 15.3 percent in August: Report

    Mumbai : The domestic formulation drug market grew by 15.3 per cent in August to Rs 9,643 crore over the corresponding month last year.


    The growth was driven by 9.1 per cent expansion in volumes, 2.9 per cent rise in prices and 3.3 per cent in new launches, according to the data compiled by pharma market research company AIOCD AWACS.


    Indian companies grew by 17.1 per cent against 9 per cent growth for MNC pharma companies during the month.


    Amongst the top 50 MNCs, Janssen grew by 23.2 per cent followed by Sanofi at 13.4 per cent and Abbott at 12.6 per cent over the same month last year.


    Among the top 50 Indian corporates, Centaur had the highest growth rate at 42.5 per cent followed by Bharat Serums at 34.4 per cent, Apex at 34 per cent and Indoco Remedies at 33.7 per cent.


    Following the regulatory ban on fixed dose combination, this segment showed a huge volume de-growth of 16.8 per cent. In revenue terms, Indian companies degrew by 11.1 per cent in the FDC portfolio whereas the MNCs degrew by 16.1 per cent, the data said.

    CentaurFDCFormulation DruggrowthIndocomarket growthMNCSanofi
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok